BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. - Wikidata - wikimedia - TriplyDB

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

http://www.wikidata.org/entity/Q39765527

about

Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma Targeting insulin and insulin-like growth factor signaling in breast cancer A Highly Selective Dual Insulin Receptor (IR)/Insulin-like Growth Factor 1 Receptor (IGF-1R) Inhibitor Derived from an Extracellular Signal-regulated Kinase (ERK) Inhibitor Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent The insulin-like growth factor-I receptor (IGF-IR) in breast cancer: biology and treatment strategies.A genome-wide screen identifies PAPP-AA-mediated IGFR signaling as a novel regulator of habituation learning.Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategy BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective prediction using large scale microarray database.Targeting insulin-like growth factor-I and insulin-like growth factor-binding protein-3 signaling pathways. A novel therapeutic approach for asthma Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.MicroRNA-21 promotes glioblastoma tumorigenesis by down-regulating insulin-like growth factor-binding protein-3 (IGFBP3).The proliferating role of insulin and insulin-like growth factors in cancer.Small-molecule ATP-competitive dual IGF-1R and insulin receptor inhibitors: structural insights, chemical diversity and molecular evolution.Targeted Therapy of Ewing's Sarcoma.Can we unlock the potential of IGF-1R inhibition in cancer therapy?Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer.Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924 Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy.Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma.High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling.The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells.Transcription factor networks as targets for therapeutic intervention of cancer: the breast cancer paradigm.Metabolic syndrome and colorectal cancer: is hyperinsulinemia/insulin receptor-mediated angiogenesis a critical process?Interventions to Slow Aging in Humans: Are We Ready?BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549.The insulin receptor: a new target for cancer therapy.Insulin activates EGFR by stimulating its interaction with IGF-1R in low-EGFR-expressing TNBC cells.Quantifying insulin receptor isoform expression in FFPE breast tumors IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias.Molecular targeted approaches for treatment of pancreatic cancer.Molecular profiling of childhood cancer: Biomarkers and novel therapies Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.

P2860

Q21129230-68F22C5D-294A-4013-B65D-5DE7F6A64A00 Q26826380-83E8AA31-46AE-4574-A20D-E344FE9FE9D1 Q27679510-59E15850-DA47-4F7E-BEAE-8F37FA150DF0 Q28484572-A7A628C9-7FD0-48E6-9FC5-C4C002B819D1 Q28543923-ECE99108-B9BF-4AA5-846D-787C6C72C501 Q30244095-576B38C2-DC5D-4BE9-9D10-F80C0217411A Q30388151-3D1E12D4-02E1-4D4F-9480-A2C01C1B7314 Q30540343-67BAD4ED-D92E-469D-BAFC-DBC8F56E89FA Q33643334-644AB4F0-E6B4-4D9D-A71E-8FE6313B8875 Q33756365-557D2D68-584A-4FF7-A427-3A05BA1BB953 Q33934670-70C4B835-9453-4026-A271-60ACDAB2E192 Q34004428-22D14243-53AA-4F65-B0F4-A649D45DC7D0 Q34139065-9C3967F0-47EE-493E-BC2D-9B388FDC87DA Q34172625-BAE1CBE1-F551-4DDA-A85F-89F7DD2E4A77 Q34186221-65705CFA-103A-4F86-8578-46BDB57F63AE Q34262377-8F86AF88-09DE-445B-AF68-77B17D37EFEF Q34336988-CCCB999A-99D3-4155-8809-8761B6ACD446 Q34391968-26E53966-8192-4E9D-AA7D-8B5927F75B11 Q34664129-E42F2226-60FE-40E2-8856-BA33DCBCC5E9 Q34674256-8FE1C1B6-931D-45BC-894D-FB42F4B30D74 Q34683782-23CACF67-ECB5-4B90-B60C-82E958656F17 Q34774874-75FF567C-2AF9-4B27-B064-F96DB7487482 Q34796287-B4489F2A-0B9D-4EA4-9B0A-DA2B9D414947 Q35013284-E0B0097E-E901-44C0-A6BE-C38BBFD377A1 Q35042972-7CB07E0F-7C53-4116-BF65-0B17A13A6167 Q35070321-2E5FAE10-17C5-4197-8D17-6EB05DB709CD Q35208383-64CA9E91-1158-4832-AC3F-F26CF6F6DB7D Q35609517-C698F290-7577-4BB9-8724-9E0AEBADB96D Q35685322-D549EC6D-160B-4632-ADA2-E2B13E6A1934 Q35876828-A5426897-00B4-4251-805D-ABD44EBFBB2F Q35923538-9ADBA500-87E8-4952-BAA8-595A4C3BF04E Q35935123-E7DD1912-773E-4704-A134-5D3B3EA10E15 Q35940305-731C7306-CB6A-4541-AD4F-CF2D45216786 Q35972002-2737D4D8-261D-48C6-8786-4AD458CE17CE Q36082594-6DDC2E9A-A2B0-4A01-B727-9F445AA46FC5 Q36084201-F8A8A3B7-20A0-4DE1-B92A-FC09DCD4AF8B Q36105608-84843F90-011E-4128-8EC8-7FCA35C86F54 Q36174910-E6BFD7AB-5C79-4C65-ABE1-787275BC36FF Q36250783-C7B8614E-835C-499E-B32F-648120DC8DF9 Q36270666-E0DF0B65-EDE8-4D4F-B783-02695FF8F459

P2860

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

http://www.wikidata.org/entity/Q39765527

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

@en

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

@nl

type

label

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

@en

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

@nl

prefLabel

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

@en

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

@nl

P1433

Q39765527-C041F26F-E603-436F-8C24-C7417D3E1EFA

P1476

Q39765527-2A72A6BB-45E4-4A2D-B37D-2ACD576246E9

P2093

Q39765527-00716DCB-8A5B-4C43-BF9F-73C8FC5C7308

Q39765527-13F41409-4DFC-40EB-B88F-D7A82F0B1E89

Q39765527-36F8FE51-100E-473B-A515-48D924CAE920

Q39765527-3CDFE4FA-8A66-412B-9ABD-1354AC5156A5

Q39765527-49749F91-470B-4E37-8F70-97944A8B8992

Q39765527-4B1EAC80-E29F-4DBA-B970-CAEE0A53E696

Q39765527-6CC930F9-DE16-4CBC-B3F8-49FBB1384873

Q39765527-6D8B7F30-2E8E-40C7-A7FA-63719CC1B95C

Q39765527-720C2863-A0AF-4681-92B0-3F9ACFCE1BB0

Q39765527-7418E79C-7C52-4885-A3AE-D7E5FB0D6C54

P304

Q39765527-AA8AC9BD-C4CE-48B3-A995-6B0FACF354CF

P31

Q39765527-017C38F6-A075-46BF-8472-14DB8B6F800B

P356

Q39765527-8BF4E743-81E9-425A-9E23-84D6CD946DCB

P433

Q39765527-AC9C7E75-8C24-4E7A-A97D-D7F08FFB0CBF

P478

Q39765527-FBD20166-9E4F-480D-AAD8-43160912F152

P577

Q39765527-5CA9C8B4-0653-442E-B5FB-3B6FB658148D

P698

Q39765527-0D64D01B-2428-4789-A6A6-C1CB64A390E8

P921

Q39765527-0812C551-561F-4BE4-83EB-42AF93BDA572

Q39765527-B404844C-3197-45BF-9B64-FED7BFDE9087

P356

1535-7163.MCT-09-0499

P1433

Molecular Cancer Therapeutics

P1476

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

@en

P2093

Aixin Li

http://www.w3.org/2001/XMLSchema#string

Ann Greer

http://www.w3.org/2001/XMLSchema#string

Carolyn Cao

http://www.w3.org/2001/XMLSchema#string

Cliff Chen

http://www.w3.org/2001/XMLSchema#string

Dolatrai Vyas

http://www.w3.org/2001/XMLSchema#string

Francis Lee

http://www.w3.org/2001/XMLSchema#string

George Trainor

http://www.w3.org/2001/XMLSchema#string

Glenn H Cantor

http://www.w3.org/2001/XMLSchema#string

Janet Dell-John

http://www.w3.org/2001/XMLSchema#string

Joan M Carboni

http://www.w3.org/2001/XMLSchema#string

P304

3341-3349

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1535-7163.MCT-09-0499

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19996272

http://www.w3.org/2001/XMLSchema#string

P921